Syncom Formulations is trading 5.3% down at ₹23.74; broad Indian healthcare weakness is the clearest available explanation, with no confirmed company-specific catalyst.
- On September 30, the Supreme Court questioned medicine markups and retail price caps. Nifty Healthcare fell 2.57%, with 19 of 20 constituents lower.
- Syncom held its 38th AGM September 30, declaring a ₹0.10-per-share FY26 final dividend; reports do not link it to the decline.
- Recent closes show a sharp pre-pullback run-up; volume data was not provided.